RadarScreener › YARW

YARW

Yarrow Bioscience, Inc.
Nasdaq · Pharmaceutical Preparations · EDGAR filings (CIK 1566044) · 15 signals · 2 setups · updated Aug 16, 2026

What the filings say Mixed ◆

Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.

Radar 82 (high attention) · dilution pressure high · listing risk elevated · governance risk elevated · runway 22.3 mo · strongest signal: New 13D filer (Aug 5, 2026)

What would confirm: Rising share count in 10-Q cover vs prior quarter; repeated 424B3 resales; another reverse split proposal.
What would prove it wrong: Notes repaid in cash / equity line terminated (8-K 1.02); share count flat quarter over quarter.

Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.

82Radar · attention score (0–100)
74Dilution pressure · financing + balance sheet
69Listing risk · exchange standards
65Governance risk · reporting, auditor, going concern

Setups

Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.

Death-spiral watch Pressure ▼ strength 0.70

Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.

Would confirm: Rising share count in 10-Q cover vs prior quarter; repeated 424B3 resales; another reverse split proposal.
Would invalidate: Notes repaid in cash / equity line terminated (8-K 1.02); share count flat quarter over quarter.
Convertible noteReverse split

Activist meets distress Mixed ◆ strength 0.55

An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.

Would confirm: 13D/A with a plan (Item 4), DEFC14A proxy contest, or 8-K 5.02 board seats.
Would invalidate: 13D/A showing the position sold down.
New 13D filer

Analyst note

No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.

Pro on YARW
Alerts
One email the morning YARW files anything that matches your rules (types, minimum score, setups).
12-month history
Every signal and setup for YARW back a year, not just 30 days — see how the current setup built.
Full analyst notes
What we noticed, evidence with links, what could prove us wrong, red-team caveats.
Full screener + CSV
All 985 flagged companies, same-day, sortable and exportable.
Get Pro · $18.85/mo founding rate   See a full Pro morning 35% off forever until Sept 30 · cancel any time

Balance sheet (XBRL)

$22.9Mcash + short-term investments as of Jun 30, 2026
22.3 moestimated runway (annualized 180-day YTD operating cash flow [companyfacts])
$22.1Mstockholders' equity as of Jun 30, 2026
$32.0Mpublic float (10-K cover)
2.7Mshares outstanding as of Aug 10, 2026 · was 33.4M May 1, 2026

Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.

Signal timeline

Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.

DateSignalEvidenceScore
Aug 13, 2026 Convertible note “convertible note” language in 8-K/A (EX-99.4) filed 2026-08-13 filing 42
Aug 13, 2026 PIPE “pipe” language in 8-K/A (EX-99.6) filed 2026-08-13 filing 36
Aug 13, 2026 Reverse split “reverse split” language in 8-K/A (EX-99.3) filed 2026-08-13 filing 32
Aug 13, 2026 Going-concern language “going concern periodic” language in 10-Q (10-Q) filed 2026-08-13 filing 18
Aug 5, 2026 New 13D filer Schedule 13D filed 2026-08-05 filing 45
Jul 30, 2026· Form 4 burst 7 Form 4 filings in 30 days filing 15
Jul 29, 2026· 13D amendment Schedule 13D/A filed 2026-07-29 filing 24
Jul 28, 2026· Change in control 8-K Item 5.01 filed 2026-07-28 (accepted 17:11 ET) filing 38
Jul 28, 2026 Unregistered sale 8-K Item 3.02 filed 2026-07-28 (accepted 17:11 ET) filing 37
Jul 28, 2026 Reverse split “reverse split” language in 8-K (EX-3.2) filed 2026-07-28 filing 37
Jul 28, 2026 PIPE “pipe” language in 8-K (8-K) filed 2026-07-28 filing 33
Jul 28, 2026 Holder rights modified 8-K Item 3.03 filed 2026-07-28 (accepted 17:11 ET) filing 30
Jul 28, 2026· Officer/director change 8-K Item 5.02 filed 2026-07-28 (accepted 17:11 ET) filing 25
Jul 21, 2026 Reverse split “reverse split” language in 8-K (8-K) filed 2026-07-21 filing 32
Jul 20, 2026 Reverse split “reverse split” language in 8-K (8-K) filed 2026-07-20 filing 32

Other death-spiral watch setups

VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · HCWB HCW Biologics Inc. · POLA Polar Power, Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · screener →

Not a subscriber yet? The free morning digest carries what changed and the top setups. Subscribe free → · Compare plans